10-K: Aditxt Faces Nasdaq Delisting Amid Deepening Losses and Going Concern Warning Despite Acquisition Push

Aditxt reported widening losses and received a Nasdaq delisting notice for its low stock price, casting substantial doubt on its ability to continue as a going concern despite ongoing acquisitions and financing efforts detailed in its annual report.

Summary

• Aditxt, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, detailing its financial condition and operational activities.
• The company operates as an innovation platform focused on discovering, developing, and deploying innovations in immune health, precision health, population health, women's health, and neurologic health through subsidiaries like Adimune, Pearsanta, and Adivir.
• Adimune is advancing its ADI-100 therapeutic candidate for autoimmune diseases like psoriasis, type 1 diabetes, and Stiff Person Syndrome, with preclinical studies completed and preparations for clinical trials underway.
• Pearsanta is developing diagnostic tests, including AditxtScore for immune profiling and Mitomic technology (acquired from MDNA Life Sciences) for early cancer detection (prostate, endometriosis) and recently acquired Adductomics technology.
• Financially, Aditxt reported revenue of $133,985 for 2024, down from $645,176 in 2023, with a net loss of $35.0 million in 2024 compared to $32.4 million in 2023.
• The company ended 2024 with $833,031 in cash and an accumulated deficit of $168.1 million, raising substantial doubt about its ability to continue as a going concern.
• Aditxt has been actively raising capital through various means, including private placements, a registered direct offering, an equity line of credit (ELOC), and an at-the-market (ATM) offering, resulting in significant dilution.
• The company is pursuing acquisitions of Evofem Biosciences and Appili Therapeutics, though the previously planned acquisition of Cellvera assets is now considered unlikely due to Cellvera's liquidation.
• Aditxt received a delisting notice from Nasdaq in March 2025 due to its low stock price, despite implementing reverse stock splits; an appeal is pending.
• Material weaknesses in internal control over financial reporting were identified related to documentation, financial statement preparation, accounts payable cutoff, and debt/equity classification.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including a going concern warning, significant losses, minimal cash, lease arrears, and a Nasdaq delisting notice. While there is pipeline potential and M&A activity, the overwhelming financial risks and uncertainties result in a very low sentiment score.

Positives

• Adimune completed preclinical studies for ADI-100, manufactured GMP clinical-grade drug substances, and engaged with regulatory agencies in Germany and the US (FDA pre-IND meeting expected Q2 2025).
• Adimune entered into a clinical trial agreement with Mayo Clinic for ADI-100 studies in CNS autoimmune diseases, starting with Stiff Person Syndrome (SPS), with trials expected in 2025.
• Pearsanta acquired the Mitomic Technology platform, expanding its diagnostic capabilities into early cancer detection using mitochondrial DNA.
• Pearsanta acquired Adductomics technology patents in March 2025, aiming to develop diagnostics assessing DNA damage before mutations occur.
• The company formed subsidiaries (Adimune, Pearsanta, Adivir, Adifem) to focus development efforts in specific therapeutic and diagnostic areas.
• Management is exploring taking the Pearsanta subsidiary public via an IPO in 2025.
• Aditxt secured additional capital through various financing agreements subsequent to year-end, including significant draws on its ELOC and ATM facilities, improving its near-term liquidity position.
• The company is actively pursuing potentially transformative acquisitions of Evofem Biosciences and Appili Therapeutics to expand its portfolio.

Negatives

• The company incurred significant net losses ($35.0M in 2024) and has a large accumulated deficit ($168.1M).
• Revenue remains minimal ($134k in 2024) and insufficient to cover operating expenses.
• There is substantial doubt about the company's ability to continue as a going concern.
• Aditxt received a delisting determination from Nasdaq due to low stock price, and continued listing is uncertain pending appeal.
• The company has a significant working capital deficit (-$21.4M as of Dec 31, 2024).
• Aditxt is significantly reliant on dilutive financing methods like ELOC and ATM offerings to fund operations.
• The company reported being significantly in arrears on lease payments for its primary facilities as of Dec 31, 2024.
• Material weaknesses were identified in the company's internal controls over financial reporting.
• The proposed acquisition of Cellvera assets is now considered unlikely due to Cellvera's liquidation.
• The company faces potential loss of rights under key technology licenses (LLU, Stanford) if milestones or payments are not met.

Risks

• The company's financial situation creates substantial doubt about its ability to continue as a going concern, requiring significant additional capital which may not be available on acceptable terms or at all.
• Failure to obtain necessary capital will prevent completion of product development and likely result in total loss for investors.
• Continued reliance on equity financing through ELOC, ATM, and other offerings will likely lead to significant further dilution for existing shareholders.
• The Nasdaq delisting process poses a significant risk; failure to regain compliance could severely impact stock liquidity and the ability to raise capital.
• Product development faces uncertainty regarding regulatory approval (FDA, international), potential clinical trial delays or failures, and demonstrating safety and efficacy.
• Even if products receive approval, successful commercialization is uncertain and depends on market acceptance, competition, pricing, and reimbursement.
• Acquisition strategy carries risks, including integration challenges, potential overpayment, failure to realize synergies, and distraction of management, particularly with the Evofem and Appili deals.
• Dependence on licensed technology from LLU and Stanford carries risks, as licenses are revocable if milestones or payments are missed.
• The company faces substantial competition from larger, better-funded companies in the biotech and diagnostics space.
• Failure to maintain CLIA certification or state laboratory licenses would halt AditxtScore testing services and harm revenue.
• Intellectual property risks include failure to obtain/maintain patents, challenges to existing patents, and potential infringement lawsuits.
• Cybersecurity threats pose risks to operations, data integrity, and confidential information.

Future Outlook

Aditxt anticipates continued net losses for the next several years as it advances its R&D efforts, clinical trials, and commercialization activities. The company requires significant additional capital to fund operations beyond the next 12 months and acknowledges substantial doubt about its ability to continue as a going concern. Future plans include advancing ADI-100 into clinical trials for psoriasis, type 1 diabetes, and SPS (expected 2025), developing Pearsanta's diagnostic pipeline (Mitomic and Adductomics tests), potentially pursuing a Pearsanta IPO in 2025, attempting to complete the acquisitions of Evofem and Appili (subject to financing and conditions), and seeking to regain Nasdaq compliance.

Management Comments

• Management believes the world needs a new approach to innovation, harnessing stakeholders to bring promising innovations to market.
• The company's business model involves securing, growing (through activation resources), and monetizing innovations via subsidiaries.
• Management acknowledges the company has generated no significant revenue, incurred substantial losses since inception ($35.0M net loss in 2024), and expects losses to continue.
• Management states the current cash position ($833k at YE 2024) is insufficient to fund operations for the next 12 months, raising substantial doubt about continuing as a going concern.
• The CEO and CFO certified that disclosure controls and procedures were evaluated and concluded to be non-effective as of December 31, 2024.
• Management identified material weaknesses in internal control over financial reporting related to documentation, financial statement drafting, accounts payable cutoff, and debt/equity classification.
• Management intends to pursue acquisitions like Evofem and Appili but notes the Cellvera deal is unlikely.
• Management highlighted progress in the Adimune (ADI-100) and Pearsanta (Mitomic, Adductomics) programs.

Industry Context

Aditxt operates in the highly competitive biotechnology and diagnostics sectors, focusing on growth areas like personalized medicine, immune modulation, and early cancer detection via liquid biopsy (Mitomic platform). Its strategy of acquiring and developing diverse assets reflects a common industry approach, though executing multiple acquisitions while facing significant financial distress is challenging. The company's struggles with cash burn, profitability, and Nasdaq compliance are characteristic of many development-stage and micro-cap biotech firms, particularly in a difficult funding environment. The push towards specialized diagnostics (AditxtScore, Mitomic tests) aligns with industry trends favoring precision health solutions.

Comparison to Industry Standards

• Aditxt's financial performance, characterized by minimal revenue ($134k in 2024) and large net losses ($35.0M in 2024), is significantly below established, profitable diagnostic or therapeutic companies like Exact Sciences or Regeneron.
• Compared to other development-stage micro-cap biotech companies, Aditxt's financial distress appears severe, highlighted by the going concern warning, Nasdaq delisting notice, and lease arrears, which are not universal even among struggling peers.
• The reliance on frequent, highly dilutive financing mechanisms (ELOC, ATM, multiple PIPEs) is common in the sector but the scale relative to market cap suggests a particularly precarious funding situation compared to companies with stronger balance sheets or clearer paths to near-term value inflection.
• Pipeline progress with ADI-100 (preclinical complete, GMP manufacturing, regulatory engagement) is standard for its stage, but meeting crucial license milestones (e.g., LLU clinical trial initiation) appears challenging, potentially lagging industry timelines for similar assets.
• The Mitomic platform acquisition positions Pearsanta in the competitive liquid biopsy space for early cancer detection, competing conceptually with larger players like Guardant Health and Freenome, although Pearsanta's technology is much earlier stage and requires significant validation.
• The identification of material weaknesses in internal controls is a significant deficiency compared to well-governed public companies and raises concerns about financial reporting reliability.

Management Changes

Corporate Governance

Legal Proceedings

• The company states it may become involved in various lawsuits and legal proceedings arising in the ordinary course of business.
• A prior counterclaim involving the company, its CEO, and CIO related to a dental practice dispute with Dr. Shabahang was dismissed with prejudice in May 2020.
• The CEO, Amro Albanna, is party to ongoing litigation unrelated to Aditxt, stemming from his prior role at Innovation Economy Corporation (IEC), which he is defending.
• A settlement was reached in January 2024 regarding a dispute with an investor over failure to register shares underlying warrants, resulting in the issuance of $1.6 million worth of common stock.

Related Party Transactions

• In February 2024, CEO Amro Albanna loaned $205,000 and $117,000 to the company; CIO Shahrokh Shabahang loaned $115,000.
• In December 2023, CEO Amro Albanna loaned $200,000 and $165,000 to the company.
• In November 2023, CEO Amro Albanna loaned $10,000 to the company.
• In June 2023, CEO Amro Albanna loaned $200,000 and CIO Shahrokh Shabahang loaned $100,000 to the company (repaid).
• In May 2023, CEO Amro Albanna loaned $200,000 to the company (repaid).
• In April 2023, CEO Amro Albanna loaned $87,523 and CIO Shahrokh Shabahang loaned $100,000 to the company (repaid).
• As of December 31, 2024, outstanding principal balances on related party notes payable totaled $115,000.
• Some related party loans were repaid subsequent to December 31, 2024.
• Rowena Albanna, the Chief Operating Officer, is the wife of Amro Albanna, the Chief Executive Officer.
• Pearsanta entered into an assignment agreement with FirstVitals LLC, an entity controlled by Pearsanta's former CEO, Ernie Lee, for IP in exchange for Pearsanta stock in November 2023.

Stakeholder Impact

• Shareholders face significant risk of further dilution due to ongoing capital raises (ELOC, ATM, potential future offerings) and potential loss of investment value due to the company's financial distress and Nasdaq delisting risk.
• Employees may face uncertainty regarding job security and the company's future viability given the financial challenges and ongoing restructuring/acquisition activities.
• Creditors, including landlords and noteholders, face risks related to the company's ability to meet its payment obligations, as evidenced by lease arrears and past defaults.
• Customers using AditxtScore services could potentially experience disruptions if financial instability impacts laboratory operations.
• Patients awaiting therapies like ADI-100 could face delays in development and availability if the company cannot secure sufficient funding for clinical trials and commercialization.

Next Steps

• Continue efforts to raise significant additional capital through ELOC, ATM, or other financing methods.
• Pursue the pending appeal with the Nasdaq Hearings Panel to avoid delisting.
• Work towards closing the acquisitions of Evofem Biosciences and Appili Therapeutics, subject to meeting closing conditions including financing.
• Advance ADI-100 towards clinical trials in psoriasis, type 1 diabetes (Germany), and Stiff Person Syndrome (US, expected 2025).
• Continue development and validation of Pearsanta's Mitomic tests (MPT, MET) and Adductomics platform.
• Explore the potential initial public offering (IPO) for the Pearsanta subsidiary in 2025.
• Remediate the identified material weaknesses in internal control over financial reporting.
• Address lease payment arrears with landlords.

Key Dates

Keywords

Aditxt, ADTX, Biotechnology, Diagnostics, Therapeutics, Immune Modulation, Personalized Medicine, Cancer Detection, Autoimmune Disease, Neurology, Pearsanta, Adimune, Mitomic Technology, AditxtScore, ADI-100, Going Concern, Nasdaq Delisting, Reverse Stock Split, Capital Raise, ELOC, ATM Offering, Evofem Biosciences, Appili Therapeutics, 10-K, Annual Report